Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionAlpha synuclein (SNCA) mAb
Molecular Target Alpha synuclein (SNCA)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today